Drug Search Results
More Filters [+]

IC-200

Alternative Names: ic-200, ic 200, ic200
Latest Update: 2024-06-10
Latest Update Note: Clinical Trial Update

Product Description

IC-200 is a gene therapy program designed by Iveric Bio. (Sourced from: https://investors.ivericbio.com/news-releases/news-release-details/iveric-bio-reports-first-quarter-2021-operational-highlights-and)

Mechanisms of Action: Gene Therapy,USH2A

Novel Mechanism: Yes

Modality: Gene Therapy

Route of Administration: Intraocular

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: IVERIC bio
Company Location: NEW YORK NY 10001
Company CEO: Glenn P. Sblendorio
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for IC-200

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Retinal Diseases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

TA032-082

N/A

Recruiting

Other

2024-09-30

TA023-207

N/A

Completed

Glaucoma

2021-12-15

Recent News Events